Lixte Biotechnology Warrants
LIXTW
LIXTW was delisted on the 26th of November, 2025.
4 hedge funds and large institutions have $173K invested in Lixte Biotechnology Warrants in 2021 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and closing their positions.
33% more funds holding
Funds holding: 3 → 4 (+1)
0.24% less ownership
Funds ownership: 0.56% → 0.32% (-0.24%)
49% less capital invested
Capital invested by funds: $339K → $173K (-$166K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$20.1K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$13K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$174K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$15.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $128K | -$174K | -182,168 | -54% |
|
|
WAM
2
Warberg Asset Management
Winnetka,
Illinois
| $22K | +$13K | +13,599 | +105% |
|
|
3
Morgan Stanley
New York
| $17K | +$20.1K | +21,053 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $6K | -$15.3K | -16,061 | -69% |
|
LIXTW Hedge Fund Activity: Q1 2021 in Review
4 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Lixte Biotechnology Warrants (LIXTW) for Q1 2021, worth a combined $173K — down 49% from $339K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new LIXTW positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $20.1K. The largest seller was Sabby Management, cutting an estimated $174K.
- 4 institutional investors held Lixte Biotechnology Warrants (LIXTW) as of Q1 2021, up from 3 in Q4 2020.
- Funds reported $173K of Lixte Biotechnology Warrants stock for Q1 2021, down 49% quarter-over-quarter.
- 1 fund opened new Lixte Biotechnology Warrants positions in Q1 2021 and 0 closed out, a net change of +1 holder.
- The largest Lixte Biotechnology Warrants buyer in Q1 2021 was Morgan Stanley, an estimated $20.1K added.
- The largest Lixte Biotechnology Warrants seller in Q1 2021 was Sabby Management, an estimated $174K sold.
Based on aggregated 13F filings for Q1 2021.